PExA published an online presentation from Life Sciencedagen in Gothenburg, where CEO Tomas Gustafsson described the company’s technology for collecting biological material from the smallest airways by analyzing particles in exhaled air. The presentation describes a non-invasive sampling method in which a specific breathing maneuver generates microscopic particles from the lung lining in deep airways for subsequent biomarker analysis. It also references current use cases in research on COPD, lung cancer and occupational lung diseases, including studies of drug effects in the lungs such as pharmacokinetics and pharmacodynamics. The release notes that a patent application has been filed related to biomarker patterns with potential for early detection of lung cancer, based on research with academic partners. The presentation recording is available at https://youtu.be/J5IV_C8DLpA and the PDF release is available at http://pexa.se/wp-content/uploads/2026/03/260317-PExA-Presentation-Life-Sciencedagen.pdf.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PExA AB published the original content used to generate this news brief on March 17, 2026, and is solely responsible for the information contained therein.